Publication Date

2017

Abstract

Angiotensin converting enzyme inhibitors ( ACE-I ), are beneficial both in heart failure with reduced ejection fraction ( HF-REF ) and after myocardial infarction ( MI ). We examined the effects of the angiotensin-receptor neprilysin inhibitor sacubitril/valsartan, compared with the ACE-I enalapril, on coronary outcomes in PARADIGM-HF.

School/Institute

Mary MacKillop Institute for Health Research

Document Type

Journal Article

Access Rights

ERA Access

Access may be restricted.

Share

COinS